Results 61 to 70 of about 131 (88)

ANALYSIS OF HYPERSENSITIVITY REACTIONS ASSOCIATED WITH THE DENGUE VACCINE IN RESIDENTS OF BELO HORIZONTE, MINAS GERAIS

Brazilian Journal of Infectious Diseases
Introduction/Objective: In December 2023, the tetravalent dengue vaccine produced by Takeda Pharmaceuticals (TAK-003) was introduced into the Brazilian vaccination schedule, supplied by the Unified Health System (SUS) to individuals aged 10 to 14 years ...
Silon de Souza Gomes Junior, Márcia Paulliny Soares Bahia, Argus Leão Araújo, Alexandre Sampaio Moura, José Geraldo Leite Ribeiro, Vitor Augusto Lima do Vale, Gabriel Roncalli Soalheiro Prado Alves   +6 more
doaj   +1 more source

Correction: Vaccination strategies, public health impact and cost-effectiveness of dengue vaccine TAK-003: A modeling case study in Thailand.

PLoS Medicine
[This corrects the article DOI: 10.1371/journal.pmed.1004631.].
Jing Shen, Elizaveta Kharitonova, Anna Tytula, Justyna Zawieja, Samuel Aballea, Shibadas Biswal, Mayuri Sharma, Supattra Rungmaitree, Rosarin Sruamsiri, Derek Wallace, Riona Hanley   +10 more
doaj   +1 more source

Advancing dengue vaccine development: Challenges, innovations, and the path toward global protection

Pediatric Investigation
Dengue fever remains a significant global health threat, placing nearly half of the world's population at risk. Despite decades of research, developing an effective dengue vaccine continues to face multiple challenges, including antibody‐dependent ...
Ran Wang, Bridget Kim, Hridesh Mishra, Kevin C. Kain   +3 more
doaj   +1 more source

The DENGVAC study: Preliminary findings on the immunogenicity of the TAK-003 dengue vaccine

Journal of Infection
Alessandra D’Abramo, Francesca Colavita, Laura Ponzetta, Patrizia De Marco, Serena Vita, Luigi Rosa, Silvia Cammisa, Eleonora Tartaglia, Laura Scorzolini, Eleonora Lalle, Eleonora Cimini, Stefania Notari, Marta Tiberi, Alba Grifoni, Daniela Weiskopf, Alessandro Sette, Linda Petrone, Fabrizio Maggi, Delia Goletti, Emanuele Nicastri   +19 more
openaire   +1 more source

TAK-003 dengue vaccine as a new tool to mitigate dengue in countries with a high disease burden

The Lancet Global Health
openaire   +2 more sources

Author Correction: The TAK-003 story: key decisions that shaped development of a tetravalent dengue vaccine

npj Vaccines
Ian Escudero, Dieter Gniel, Shibadas Biswal, Eckhardt Petri, Gonzalo Perez, Mayuri Sharma, John Weil, Derek Wallace   +7 more
doaj   +1 more source

Estado actual de las vacunas contra el dengue, confoco en TAK-003 (Qdenga®)

Archivos Argentinos de Pediatria
openaire   +1 more source

Some of the next articles are maybe not open access.

Related searches:

A new dengue vaccine (TAK-003) now WHO recommended in endemic areas; what about travellers?

Journal of Travel Medicine, 2023
Qdenga (Takeda) is now WHO recommended for residents of highly endemic areas. Travellers from dengue non-endemic countries with previous travel-related dengue (any serotype) will benefit from TAK-003 vaccination to prevent a secondary dengue infection during future dengue risk travel.
David O Freedman, Freedman David O
exaly   +3 more sources

Effectiveness of the TAK-003 dengue vaccine in adolescents during the 2024 outbreak in São Paulo, Brazil: a test-negative, case–control study

Lancet Infectious Diseases, The
Dengue is a substantial public health challenge in tropical regions, and is considered a global health threat owing to its expanding geographical range and increasing incidence as a result of climate change. Despite the availability of tetravalent dengue vaccines, real-world evidence on their effectiveness is scarce.
Otavio T, Ranzani, Felippe, Lazar Neto, Lisany Krug, Mareto, Thiago Sanches, Brumatti, Roberto Dias, de Oliveira, Patricia Vieira, da Silva, Edinéia Ribeiro, Dos Santos, Tatiana Lang, D' Agostini, Regiane A Cardoso, De Paula, Natalie E, Dean, Albert I, Ko, Derek A T, Cummings, Jason R, Andrews, Matt D T, Hitchings, Julio, Croda   +14 more
exaly   +3 more sources

Immunogenicity of a Live Dengue Vaccine (TAK-003)

The Journal of Infectious Diseases, 2022
Aravinda, de Silva, Laura, White
openaire   +2 more sources